Curcumin Sensitizes Silymarin to Exert Synergistic Anticancer Activity in Colon Cancer Cells

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Jul 9

PMID 27390600

Citations 24

Authors

Amanda Montgomery

Temitope Adeyeni

KayKay San

Rita M Heuertz

Uthayashanker R Ezekiel

Affiliations

Soon will be listed here.

Abstract

We studied combinatorial interactions of two phytochemicals, curcumin and silymarin, in their action against cancer cell proliferation. Curcumin is the major component of the spice turmeric. Silymarin is a bioactive component of milk thistle used as a protective supplement against liver disease. We studied antiproliferative effects of curcumin alone, silymarin alone and combinations of curcumin and silymarin using colon cancer cell lines (DLD-1, HCT116, LoVo). Curcumin inhibited colon cancer cell proliferation in a concentration-dependent manner, whereas silymarin showed significant inhibition only at the highest concentrations assessed. We found synergistic effects when colon cancer cells were treated with curcumin and silymarin together. The combination treatment led to inhibition of colon cancer cell proliferation and increased apoptosis compared to single compound treated cells. Combination treated cells exhibited marked cell rounding and membrane blebbing of apoptotic cells. Curcumin treated cells showed 3-fold more caspase3/7 activity whereas combination treated cells showed 5-fold more activity compared to control and silymarin treated cells. When DLD-1 cells were pre-exposed to curcumin, followed by treatment with silymarin, the cells underwent a high amount of cell death. The pre-exposure studies indicated curcumin sensitization of silymarin effect. Our results indicate that combinatorial treatments using phytochemicals are effective against colorectal cancer.

Citing Articles

Natural polyphenols: A protective approach to reduce colorectal cancer.

Okpoghono J, Isoje E, Igbuku U, Ekayoda O, Omoike G, Adonor T Heliyon. 2024; 10(11):e32390.

PMID: 38961927 PMC: 11219337. DOI: 10.1016/j.heliyon.2024.e32390.

Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy.

Rauf A, Joshi P, Olatunde A, Hafeez N, Ahmad Z, Hemeg H Med Oncol. 2024; 41(5):122.

PMID: 38652344 DOI: 10.1007/s12032-024-02368-8.

A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer.

Kandhavelu J, Subramanian K, Naidoo V, Sebastianelli G, Doan P, Konda Mani S Br J Pharmacol. 2023; 181(1):107-124.

PMID: 37183661 PMC: 10952184. DOI: 10.1111/bph.16141.

Strategies for Improving Bioavailability, Bioactivity, and Physical-Chemical Behavior of Curcumin.

Racz L, Racz C, Pop L, Tomoaia G, Mocanu A, Barbu I Molecules. 2022; 27(20).

PMID: 36296447 PMC: 9608994. DOI: 10.3390/molecules27206854.

Ethnomedicinal uses of Indian spices used for cancer treatment: A treatise on structure-activity relationship and signaling pathways.

Singh N, Singh Yadav S Curr Res Food Sci. 2022; 5:1845-1872.

PMID: 36276240 PMC: 9579211. DOI: 10.1016/j.crfs.2022.10.005.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Gambhir S, Vyas D, Hollis M, Aekka A, Vyas A . Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. World J Gastroenterol. 2015; 21(11):3174-83. PMC: 4363746. DOI: 10.3748/wjg.v21.i11.3174. View

Gupta S, Sung B, Kim J, Prasad S, Li S, Aggarwal B . Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol Nutr Food Res. 2012; 57(9):1510-28. DOI: 10.1002/mnfr.201100741. View

Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

de Paiva Goncalves V, Ortega A, Guimaraes M, Curylofo F, Rossa Junior C, Ribeiro D . Chemopreventive activity of systemically administered curcumin on oral cancer in the 4-nitroquinoline 1-oxide model. J Cell Biochem. 2014; 116(5):787-96. DOI: 10.1002/jcb.25035. View

Zhang J, Lin M, Zhou M, Yi T, Tang Y, Tang S . Combinational Treatment of Curcumin and Quercetin against Gastric Cancer MGC-803 Cells in Vitro. Molecules. 2015; 20(6):11524-34. PMC: 6272649. DOI: 10.3390/molecules200611524. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Carroll R, Benya R, Turgeon D, Vareed S, Neuman M, Rodriguez L . Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011; 4(3):354-64. PMC: 4136551. DOI: 10.1158/1940-6207.CAPR-10-0098. View

Gao X, Wang B, Wu Q, Wei X, Zheng F, Men K . Combined Delivery and Anti-Cancer Activity of Paclitaxel and Curcumin Using Polymeric Micelles. J Biomed Nanotechnol. 2015; 11(4):578-89. DOI: 10.1166/jbn.2015.1964. View

10.

Chang T, Chou T . Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan. 2001; 41(6):294-302. View

11.

Pesakhov S, Khanin M, Studzinski G, Danilenko M . Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer. 2010; 62(6):811-24. PMC: 2911976. DOI: 10.1080/01635581003693082. View

12.

Deguchi A . Curcumin targets in inflammation and cancer. Endocr Metab Immune Disord Drug Targets. 2015; 15(2):88-96. DOI: 10.2174/1871530315666150316120458. View

13.

Anand P, Sundaram C, Jhurani S, Kunnumakkara A, Aggarwal B . Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008; 267(1):133-64. DOI: 10.1016/j.canlet.2008.03.025. View

14.

Manna S, Mukhopadhyay A, Van N, Aggarwal B . Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999; 163(12):6800-9. View

15.

Basile V, Belluti S, Ferrari E, Gozzoli C, Ganassi S, Quaglino D . bis-Dehydroxy-Curcumin triggers mitochondrial-associated cell death in human colon cancer cells through ER-stress induced autophagy. PLoS One. 2013; 8(1):e53664. PMC: 3543386. DOI: 10.1371/journal.pone.0053664. View

16.

Miroliaee A, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi A, Abdollahi M . Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech Methods. 2011; 21(3):200-8. DOI: 10.3109/15376516.2010.547887. View

17.

Tong L, Yuan Y, Wu S . Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev. 2014; 81:1-15. PMC: 4274225. DOI: 10.1016/j.addr.2014.09.004. View

18.

Shehzad A, Wahid F, Lee Y . Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim). 2010; 343(9):489-99. DOI: 10.1002/ardp.200900319. View

19.

Bandugula V, N R . 2-Deoxy-D-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells. Tumour Biol. 2012; 34(1):251-9. DOI: 10.1007/s13277-012-0545-6. View

20.

Shehzad A, Lee J, Huh T, Lee Y . Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53. Mol Cells. 2013; 35(6):526-32. PMC: 3887881. DOI: 10.1007/s10059-013-0038-5. View